## Divyanshu Dubey

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/892901/publications.pdf

Version: 2024-02-01

75 papers 4,408 citations

30 h-index 62 g-index

75 all docs

75 docs citations

75 times ranked 3032 citing authors

#	Article	IF	CITATIONS
1	Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 112-114.	1.9	13
2	Clinical Sensitivity, Specificity, and Predictive Value of Neural Antibody Testing for Autoimmune Encephalitis. journal of applied laboratory medicine, The, 2022, 7, 350-356.	1.3	18
3	LGI1 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	1.9	48
4	CASPR2â€IgGâ€associated autoimmune seizures. Epilepsia, 2022, 63, 709-722.	5.1	14
5	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clinic Proceedings, 2022, 97, 547-559.	3.0	29
6	Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 196-200.	1.9	20
7	Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	29
8	Paraneoplastic neurological syndrome: growing spectrum and relevance. Neurological Sciences, 2022, 43, 3583-3594.	1.9	4
9	$\hat{I}^2$ IV-Spectrin Autoantibodies in 2 Individuals With Neuropathy of Possible Paraneoplastic Origin. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	4
10	Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults. JAMA Neurology, 2022, 79, 808.	9.0	10
11	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	3.0	64
12	Teaching Neurolmages: Brain and Skin Involvement in Erdheim-Chester Disease. Neurology, 2021, 96, e1590-e1592.	1.1	1
13	Paraneoplastic Myeloneuropathies. Neurology, 2021, 96, e632-e639.	1.1	26
14	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Communications, 2021, 3, fcaa233.	3.3	31
15	Paraneoplastic neurological syndromes: clinical presentations and management. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098532.	3.5	41
16	Clinical spectrum of high-titre GAD65 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 645-654.	1.9	84
17	Teaching Video Neurolmages: Periodic Alternating Nystagmus in Paraneoplastic KLHL11 Rhomboencephalitis. Neurology, 2021, 96, e2668-e2669.	1.1	6
18	Paraneoplastic neurological syndrome: an evolving story. Neuro-Oncology Practice, 2021, 8, 362-374.	1.6	5

#	Article	IF	Citations
19	Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. Annals of Neurology, 2021, 89, 1001-1010.	5.3	27
20	Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. Epilepsia, 2021, 62, e76-e81.	5.1	13
21	Focal sensory chronic inflammatory demyelinating polyneuropathy ( <scp>CIDP</scp> ). Muscle and Nerve, 2021, 63, E46-E49.	2.2	1
22	Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy. Neurology, 2021, 96, e2078-e2089.	1.1	8
23	Clinical Reasoning: A 49-Year-Old Woman With Progressive Numbness and Gait Instability. Neurology, 2021, 97, 342-347.	1.1	2
24	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	313
25	Clinical Utility of Antiretinal Antibody Testing. JAMA Ophthalmology, 2021, 139, 658.	2.5	18
26	Paraneoplastic cochleovestibulopathy: clinical presentations, oncological and serological associations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1181-1185.	1.9	14
27	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors., 2021, 9, e002890.		87
28	Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis. Neurology, 2021, 97, e1141-e1149.	1.1	27
29	Ondine's Curse and Trismus in Association With Kelch-like Protein-11 Autoimmunity. JAMA Neurology, 2021, 78, 1016.	9.0	5
30	003â€Autoimmune encephalitis antibody biomarkers: frequency, age and sex associations. , 2021, , .		0
31	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. Neurology, 2021, 97, e1351-e1358.	1.1	25
32	Pure Motor Onset and IgM-Gammopathy Occurrence in Multifocal Acquired Demyelinating Sensory and Motor Neuropathy. Neurology, 2021, 97, .	1.1	5
33	Neurofascin-155 Immunoglobulin Subtypes. Neurology, 2021, 97, .	1.1	17
34	Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. Annals of Clinical and Translational Neurology, 2021, 8, 425-439.	3.7	16
35	Collapsin Response-Mediator Protein 5–Associated Retinitis, Vitritis, and Optic Disc Edema. Ophthalmology, 2020, 127, 221-229.	5 <b>.</b> 2	25
36	Randomized Placebo ontrolled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Annals of Neurology, 2020, 87, 313-323.	<b>5.</b> 3	106

#	Article	IF	CITATIONS
37	IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 324-326.	1.9	4
38	Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-lgG. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 328-330.	1.9	25
39	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clinical Chemistry, 2020, 66, 1496-1509.	3.2	41
40	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurology, 2020, 77, 1420.	9.0	109
41	Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm. Neurology, 2020, 95, e3002-e3011.	1.1	14
42	Neurologic autoimmunity and immune checkpoint inhibitors. Neurology, 2020, 95, e2442-e2452.	1.1	94
43	Reply to "Value of Onconeural Antibodies in Checkpoint Inhibitorâ€Related Toxicities― Annals of Neurology, 2020, 88, 200-201.	5.3	1
44	Contactin-1 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e771.	6.0	15
45	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology, 2020, 95, e111-e120.	1.1	140
46	Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. Journal of Neurology, 2020, 267, 3337-3342.	3.6	15
47	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Annals of Neurology, 2020, 87, 659-669.	5.3	137
48	Autoimmune psychosis. Lancet Psychiatry,the, 2020, 7, 122.	7.4	4
49	GFAP IgG associated inflammatory polyneuropathy. Journal of Neuroimmunology, 2020, 343, 577233.	2.3	14
50	Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. New England Journal of Medicine, 2019, 381, 47-54.	27.0	169
51	Amphiphysin-lgG autoimmune neuropathy. Neurology, 2019, 93, e1873-e1880.	1.1	41
52	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology, 2019, 93, e1093-e1103.	1.1	107
53	Autoimmune Epilepsy. Neurotherapeutics, 2019, 16, 685-702.	4.4	83
54	Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. Epilepsia, 2019, 60, 367-369.	5.1	43

#	Article	IF	CITATIONS
55	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurology, 2019, 76, 301.	9.0	243
56	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of Neurology, 2018, 83, 166-177.	5.3	479
57	Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology, 2018, 90, e103-e110.	1.1	86
58	Paraneoplastic neuronal intermediate filament autoimmunity. Neurology, 2018, 91, e1677-e1689.	1.1	50
59	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.1	129
60	Botulinum Toxin in Restless Legs Syndromeâ€"A Randomized Double-Blind Placebo-Controlled Crossover Study. Toxins, 2018, 10, 401.	3.4	12
61	Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1†year. Journal of Neuroimmunology, 2018, 321, 157-163.	2.3	136
62	LGI1 and CASPR2 neurological autoimmunity in children. Annals of Neurology, 2018, 84, 473-480.	5.3	53
63	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. Journal of Neuroimmunology, 2018, 323, 62-72.	2.3	68
64	Association of MOG-lgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-lgG–Associated Disorders. JAMA Neurology, 2018, 75, 1355.	9.0	286
65	PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome. Journal of Neuroimmunology, 2018, 323, 53-55.	2.3	1
66	Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. Parkinsonism and Related Disorders, 2018, 56, 65-69.	2.2	31
67	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2017, 74, 359.	9.0	38
68	Considering Spastic Paraplegia Type 7 and Adult-Onset Alexander Disease—Reply. JAMA Neurology, 2017, 74, 869.	9.0	0
69	Smartphone Apps as a Source of Information About Interventional Radiology. CardioVascular and Interventional Radiology, 2017, 40, 957-958.	2.0	5
70	Expanded phenotypes and outcomes among 256 <scp>LGI</scp> 1/ <scp>CASPR</scp> 2â€ <scp>I</scp> g <scp>G</scp> â€"positive patients. Annals of Neurology, 2017, 82, 79-92.	5.3	242
71	Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017, 58, 1181-1189.	5.1	120
72	Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain, 2017, 140, 2415-2425.	7.6	158

#	Article	IF	CITATIONS
73	Botulinum Toxin in Parkinson Disease Tremor. Mayo Clinic Proceedings, 2017, 92, 1359-1367.	3.0	46
74	B-cell–targeted therapies in relapsing forms of MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e405.	6.0	10
75	Smartphone Applications Providing Information about Stroke: Are We Missing Stroke Risk Computation Preventive Applications?. Journal of Stroke, 2017, 19, 117-117.	3.2	3